Podoplanin overexpression in human mesothelioma cell lines enhances the tumorigenic phenotype

Ei Yamaki1, Toshiki Yajima, Takayuki Kosaka

  • 1Department of General Surgical Science, Gunma University Graduate School of Medicine, Gunma, Japan. eymk@showa.gunma-u.ac.jp

Oncology Reports
|January 8, 2013
PubMed

Insights

Podoplanin promotes malignant pleural mesothelioma (MPM) cell invasion and resistance to apoptosis. Silencing podoplanin restores sensitivity to chemotherapy, suggesting it is a potential therapeutic target for MPM.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Biology

Background:

  • Podoplanin is a known diagnostic marker for malignant pleural mesothelioma (MPM).
  • The physiological role of podoplanin in MPM pathogenesis remains unclear.

Purpose of the Study:

  • To investigate the functional role of podoplanin in MPM.
  • To explore podoplanin's contribution to mesothelioma cell invasiveness and apoptosis resistance.

Main Methods:

  • Generated mesothelioma cell lines with stable high podoplanin expression (PODO1, PODO2).
  • Assessed cell proliferation, survival in mice, in vitro invasion, matrix metalloproteinase-1 (MMP-1) expression, and apoptosis induction.
  • Utilized RNA interference to silence podoplanin and examined apoptosis sensitivity to cis-diamminedichloroplatinum(II) (CDDP).

Main Results:

  • High podoplanin expression increased mesothelioma cell invasiveness and MMP-1 upregulation.
  • Podoplanin-expressing cells exhibited resistance to apoptosis induced by starvation or CDDP.
  • Silencing podoplanin restored CDDP-induced apoptosis, and constitutive extracellular signal-regulated kinase (ERK) activation was observed.

Conclusions:

  • Constitutive podoplanin expression enhances invasive growth and apoptosis resistance in MPM cells.
  • Podoplanin signaling pathways represent potential therapeutic targets for novel MPM treatments.